Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage…
Read More...
Read More...
Browsing Tag
Crinetics
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan…
- Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 – - Initiation of patient dosing…
Read More...
Read More...
Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic…
CRN04894 Phase 1 Study Progressing to Multiple Ascending Dose Cohorts Management Hosting Webcast and Conference…
Read More...
Read More...